Exact Sciences: Cancer Detection Stalwart's Bad Quarter Resets Its Overgrown Market Cap.
Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...
medtechdive3d
Exact Sciences’ forecast cut shocks analysts
The lowered sales forecast, which analysts called a “shocking guidance update,” contributed to a 23% drop in the cancer ...
Investor's Business Daily on MSN3d
Guardant Health Pops 13% On An 'Impressive' Beat Following Exact Sciences' Flop
Guardant Health stock jumped Thursday on an "impressive" third-quarter report following the launch of its cancer detection test, Shield.Please watch the video at Investors.com - Biotech Stocks Are ...
Cologuard Maker Exact Sciences Slashes Outlook as Losses Mount
Key Takeaways Exact Sciences shares plunged Wednesday after the company reported widening losses. The maker of the Cologuard colon cancer screening test lowered its full-year outlook.CEO Kevin Conroy ...
Exact Sciences price target lowered to $75 from $95 at Canaccord
Canaccord analyst Kyle Mikson lowered the firm’s price target on Exact Sciences (EXAS) to $75 from $95 and keeps a Buy rating on the ...
Exact Sciences Reports Strong Q3 Performance and Pipeline Advances
Exact Sciences Corp ( (EXAS) ) has released its Q3 earnings. Here is a breakdown of the information Exact Sciences Corp presented to its ...